Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Single-dose Rituximab Biosimilar in the Initial Episode of Paediatric Steroid-sensitive Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial

NCT05850546 is registered in ClinicalTrials.gov with Children's Hospital of Fudan University as lead sponsor.

NCT NCT05850546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05850546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Single-dose Rituximab Biosimilar in the Initial Episode of Paediatric Steroid-sensitive Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial
Lead sponsor
Children's Hospital of Fudan University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
March 1, 2025
Completion date
December 28, 2026
Enrollment
138 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

steroid-sensitive nephrotic syndrome